FCN-338/LOXO-338: FCN-338 is a selective BCL2 inhibitor developed by Fochon Pharmaceutical (https://fochonpharma.com) which displayed nanomolar potency against a range of BCL2-dependent FL, DLBCL, AML and ALL cell lines in vitro.346,347 Dose-dependent tumor growth inhibition was observed in FL, AML, and ALL xenograft models without significant weight loss. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.